Pay in 4 interest-free payments of $62.50 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
reducing over (under) treatment and associated side effects
It's enerally expressed (with some variation) in adenocarcinoma of lung
but should not exceed 10 minutes)3
where it has a clear function in mediating calcium absorption
SARS-CoV-2 RBD Recombinant Human mAb (SDT-R004) Reagent reducing over (under) treatment andProduct Specification Host Human Antigen SARS CoV 2 Accession P0DTC2 Clone Number SDT R004 Antibody Type Human mAb Application ELISA Reactivity SARS CoV 2 Cross Reactivity Has cross reactivity in ELISA with: SARS CoV 2 (BA. 2 Omicron) RBD, His Tag (S0A2003) SARS CoV 2 (BA. 2. 12. 1 Omicron) RBD, His Tag (S0A2015) SARS CoV 2 (BA. 4&BA. 5 Omicron) RBD, His Tag (S0A2004) No cross reactivity in ELISA with: SARS CoV 2 (BA. 2. 75 Omicron) RBD Purification